P. Kent Hawryluk Acquires 18,500 Shares of MBX Biosciences (NASDAQ:MBX) Stock

MBX Biosciences, Inc. (NASDAQ:MBX) CEO P. Kent Hawryluk bought 18,500 shares of MBX Biosciences stock in a transaction that occurred on Friday, March 13th. The shares were acquired at an average cost of $28.41 per share, for a total transaction of $525,585.00. Following the acquisition, the chief executive officer owned 486,777 shares in the company, valued at $13,829,334.57. The trade was a 3.95% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

MBX Biosciences Stock Down 0.2%

MBX Biosciences stock opened at $29.74 on Wednesday. The firm has a fifty day simple moving average of $35.60 and a two-hundred day simple moving average of $26.91. MBX Biosciences, Inc. has a twelve month low of $4.81 and a twelve month high of $44.89. The company has a market capitalization of $1.41 billion, a PE ratio of -12.34 and a beta of 1.06.

MBX Biosciences (NASDAQ:MBX) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.15.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MBX. The Goldman Sachs Group started coverage on MBX Biosciences in a research note on Thursday, December 4th. They issued a “sell” rating and a $18.00 price target on the stock. Barclays started coverage on shares of MBX Biosciences in a report on Tuesday, January 27th. They issued an “overweight” rating and a $66.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of MBX Biosciences in a report on Thursday, January 22nd. Guggenheim increased their price target on shares of MBX Biosciences from $77.00 to $88.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Finally, Truist Financial set a $50.00 price objective on shares of MBX Biosciences in a research report on Monday, March 9th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, MBX Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $51.56.

Institutional Trading of MBX Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of MBX. GF Fund Management CO. LTD. bought a new position in shares of MBX Biosciences in the 4th quarter worth $28,000. Russell Investments Group Ltd. boosted its position in MBX Biosciences by 4,131.4% during the third quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock valued at $26,000 after purchasing an additional 1,446 shares in the last quarter. Royal Bank of Canada grew its stake in MBX Biosciences by 59.6% in the fourth quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock valued at $49,000 after purchasing an additional 572 shares during the last quarter. FNY Investment Advisers LLC bought a new position in MBX Biosciences in the third quarter worth about $27,000. Finally, California State Teachers Retirement System lifted its position in shares of MBX Biosciences by 64.7% during the fourth quarter. California State Teachers Retirement System now owns 1,754 shares of the company’s stock valued at $55,000 after buying an additional 689 shares during the last quarter.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.